Drug Search Results
More Filters [+]

Crotedumab

Alternative Names: Crotedumab, regn-1193, regn1193, regn 1193
Latest Update: 2016-05-12
Latest Update Note: Clinical Trial Update

Product Description

Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that functionally antagonises activity of the glucagon receptor (GCGR) in vitro (Sourced from: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=9614)

Mechanisms of Action: GcGr Blocker

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Crotedumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Healthy Volunteers|Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

R1193-DM-1402

P1

Terminated

Type 2 Diabetes

2015-12-01

R1193-HV-1219

P1

Completed

Healthy Volunteers

2015-01-01

Recent News Events

Date

Type

Title